Although the body of literature remains limited, retrospective studies have consistently shown that combined loss of p16 and MTAP expression is strongly associated with lesions ultimately classified as melanoma or high-risk melanocytomas [46]. The gene discussed is CDKN2A; the disease is melanoma.